Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Geron Corp. (NASDAQ: GERN).

Full DD Report for GERN

You must become a subscriber to view this report.


Recent News from (NASDAQ: GERN)

Geron Announces Oral Presentation at European Hematology Association Congress
MENLO PARK, Calif., May 17, 2018 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq:GERN) today announced that an abstract describing clinical data regarding the telomerase inhibitor imetelstat has been selected for an oral presentation at the 23rd Congress of the European Hematology Association...
Source: GlobeNewswire
Date: May, 17 2018 09:05
Recent Analysis Shows H&R Block, Opko Health, Geron, Cardinal Health, Corning, and Intrexon Market Influences - Renewed Outlook, Key Drivers of Growth
NEW YORK, May 16, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of H&R Block, Inc. (NYSE:HRB), Opko Health, Inc. (NASDAQ:OPK), Geron Corp...
Source: GlobeNewswire
Date: May, 16 2018 07:45
Geron down 8% premarket after Q1 report
Geron (NASDAQ: GERN ) Q1 results ($M): Revenues from licence fees & royalties: 0.3 (-40.8%); Net loss: (7.2) (flat). More news on: Geron Corporation, Healthcare stocks news, Stocks on the move, Earnings news and commentary, Read more ...
Source: SeekingAlpha
Date: May, 11 2018 08:20
Geron beats by $0.01
Geron (NASDAQ: GERN ): Q1 EPS of -$0.04 beats by $0.01 . Revenue of $0.32M (-40.7% Y/Y) Shares +1.9% . Press Release More news on: Geron Corporation, Earnings news and commentary, Stocks on the move, Healthcare stocks news,
Source: SeekingAlpha
Date: May, 10 2018 16:16
Geron Corporation Reports First Quarter 2018 Financial Results
MENLO PARK, Calif., May 10, 2018 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq:GERN) today reported financial results for the first quarter ended March 31, 2018. First Quarter 2018 Results For the first quarter of 2018, the company reported operating revenues of $318,000 and operatin...
Source: GlobeNewswire
Date: May, 10 2018 16:10
Today's Research Reports on Trending Tickers: Geron Corporation and Nektar Therapeutics
NEW YORK, NY / ACCESSWIRE / May 7, 2018 / U.S. markets rallied on Friday, despite trade uncertainties and weak employment data, as a surge in Apple led to strong gains by the tech sector. The Dow Jones Industrial Average gained 1.39 percent to close at 24,262.51, while the S&P 500 Index...
Source: ACCESSWIRE IA
Date: May, 07 2018 08:20
The No BS Report, Week 12: Living In Yawnsville With Little But Gains
Author's note: As always, I'm happy to answer questions in the comments below, but you can get direct access to me in the Total Pharma Tracker chatroom if you want to discuss in further detail! Right now you can get a no-obligation free trial to the service for two weeks. Welcome to an...
Source: SeekingAlpha
Date: May, 06 2018 08:58
Liking Box Since $12 - Cramer's Lightning Round (5/1/18)
Stocks discussed on the Lightning Round segment of Jim Cramer's Mad Money Program, Tuesday, May 1. Bullish Calls Box (BOX): Cramer has liked the stock since $12. CEO Aaron Levie is good. Applied Materials (AMAT): "I know a lot of people are selling Applied Materials because they feel l...
Source: SeekingAlpha
Date: May, 02 2018 06:42
It's Illogical To Think That Johnson & Johnson Has Dropped Geron
Background Story Imetelstat, a first-in-class telomerase inhibitor and Geron's sole product candidate, is currently in phase 2 (IMbark) and phase 2/3 (IMerge) clinical trials. Ever since Geron and JNJ announced a joint collaboration agreement in November 2014 to develop and commerciali...
Source: SeekingAlpha
Date: May, 01 2018 16:12
Geron Bear V. Bull - 50¢ Or $50
Geron ( GERN ) is a tiny biotech, <$1 billion market cap, with an oversized history and an undersized pipeline. Its CEO has managed to steer the company through the wilderness within clear sight of the promised land. He expects that by Q3 2018, Johnson & Johnson's ( JNJ ) subsidia...
Source: SeekingAlpha
Date: May, 01 2018 00:05

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-08-173.923.924.053.842,280,822
2018-08-163.873.913.963.801,267,855
2018-08-153.953.8353.963.752,225,868
2018-08-143.933.904.11993.883,295,290
2018-08-133.843.90083.953.782,031,548

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-08-17680,086883,26676.9967Short
2018-08-16404,728585,86669.0820Short
2018-08-15565,982826,87168.4486Short
2018-08-14711,2481,203,20959.1126Short
2018-08-13318,071653,35248.6829Short

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on GERN.


About Geron Corp. (NASDAQ: GERN)

Logo for Geron Corp. (NASDAQ: GERN)

Not available

 

Contact Information

 

 

Current Management

  • Ronald W. Eastman / President, CEO
  • David L. Greenwood / CFO, Secretary

Current Share Structure

  • Market Cap: $528,551,749 - 05/16/2018
  • Issue and Outstanding: 160,654,027 - 03/07/2018

 


Recent Filings from (NASDAQ: GERN)

Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: May, 10 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: May, 10 2018
Official notification to shareholders of matters to be brought to a vote (Proxy)
Filing Type: DEF 14AFiling Source: edgar
Filing Date: March, 30 2018
Additional proxy soliciting materials - definitive
Filing Type: DEFA14AFiling Source: edgar
Filing Date: March, 30 2018
Annual report with a comprehensive overview of the company
Filing Type: 10-KFiling Source: edgar
Filing Date: March, 16 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: March, 16 2018
Amendment to the SC 13G filing
Filing Type: SC 13G/AFiling Source: edgar
Filing Date: February, 13 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: February, 02 2018
Amendment to the SC 13G filing
Filing Type: SC 13G/AFiling Source: edgar
Filing Date: January, 25 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: January, 08 2018

 

 


Daily Technical Chart for (NASDAQ: GERN)

Daily Technical Chart for (NASDAQ: GERN)


Stay tuned for daily updates and more on (NASDAQ: GERN)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (NASDAQ: GERN)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

DD Report
@DDReports

 

 


Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in GERN is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received up to $100,000 worth of crypto currency from a non-affiliated third party for the publication and circulation of this report. DD Report does not own any shares of GERN and does not buy, sell, or trade any shares of GERN. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: http://dd.report/disclaimer/